Altimmune (ALT) Amortization of Deferred Charges (2010 - 2026)

Altimmune (ALT) reported Amortization of Deferred Charges of $218000.0 for Q1 2026, up 13.54% quarter-over-quarter from $192000.0 in Q4 2025.

Altimmune (ALT) Amortization of Deferred Charges (2010 - 2026) Analysis & Trends

Altimmune (ALT) has 10 years of Amortization of Deferred Charges data on file, last reported at $218000.0 in Q1 2026.

Amortization of Deferred Charges for Q1 2026 came in at $218000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $583587.0 (changed N/A YoY), and the FY2025 annual result was $363000.0, changed N/A from the prior year.
Amortization of Deferred Charges improved to $218000.0 in Q1 2026 per ALT's latest filing, from $192000.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $218000.0 in Q1 2026 and troughed at $113000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Altimmune	336.67 Mn	336.67 Mn	-

Download Data